DK2371361T3 - Fremgangsmåder til mobilisering af progenitor-/stamceller - Google Patents

Fremgangsmåder til mobilisering af progenitor-/stamceller Download PDF

Info

Publication number: DK2371361T3
Authority: DK; Denmark
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

DK10184509.7T

Other languages

English (en)

Inventor

Gary J Bridger

Michael J Abrams

Geoffrey W Henson

Gary B Calandra

C David Dale

Hal E Broxmeyer

Ronald Trevor Macfarland

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2002-07-30

Publication date

2019-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2371361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-07-30 Application filed by Genzyme Corp filed Critical Genzyme Corp

2019-08-19 Application granted granted Critical

2019-08-19 Publication of DK2371361T3 publication Critical patent/DK2371361T3/da

Links

210000000130 stem cell Anatomy 0.000 title abstract 4
230000001483 mobilizing effect Effects 0.000 title 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
125000003118 aryl group Chemical group 0.000 abstract 3
125000004122 cyclic group Chemical group 0.000 abstract 3
229910052757 nitrogen Inorganic materials 0.000 abstract 3
125000002947 alkylene group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000000468 ketone group Chemical group 0.000 abstract 1
125000005647 linker group Chemical group 0.000 abstract 1
125000002950 monocyclic group Chemical group 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
229920000768 polyamine Polymers 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK10184509.7T 2001-07-31 2002-07-30 Fremgangsmåder til mobilisering af progenitor-/stamceller DK2371361T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
EP02750370A EP1411918B1 (en)	2001-07-31	2002-07-30	Methods to mobilize progenitor/stem cells

Publications (1)

Publication Number	Publication Date
DK2371361T3 true DK2371361T3 (da)	2019-08-19

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK02750370.5T DK1411918T3 (da)	2001-07-31	2002-07-30	Fremgangsmåder til at mobilisere progenitor/stamceller
DK10184509.7T DK2371361T3 (da)	2001-07-31	2002-07-30	Fremgangsmåder til mobilisering af progenitor-/stamceller

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK02750370.5T DK1411918T3 (da)	2001-07-31	2002-07-30	Fremgangsmåder til at mobilisere progenitor/stamceller

Country Status (28)

Country	Link
US (9)	US6987102B2 (da)
EP (3)	EP1411918B1 (da)
JP (2)	JP5137288B2 (da)
KR (2)	KR20040020075A (da)
CN (2)	CN102302493B (da)
AT (1)	ATE538785T1 (da)
AU (1)	AU2002318927B2 (da)
BE (1)	BE2019C544I2 (da)
BR (1)	BRPI0211570B8 (da)
CA (1)	CA2455559C (da)
CY (4)	CY1112633T1 (da)
DK (2)	DK1411918T3 (da)
ES (2)	ES2380009T3 (da)
FR (2)	FR12C0042I1 (da)
HU (1)	HUP0402360A2 (da)
IL (2)	IL159312A0 (da)
LT (2)	LT2371361T (da)
LU (2)	LU92033I2 (da)
MX (1)	MXPA04000982A (da)
NL (2)	NL300537I2 (da)
NO (4)	NO336989B1 (da)
NZ (1)	NZ530169A (da)
PL (1)	PL364673A1 (da)
PT (2)	PT1411918E (da)
RU (1)	RU2309741C2 (da)
SI (2)	SI2371361T1 (da)
WO (1)	WO2003011277A2 (da)
ZA (1)	ZA200400658B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
DK1411918T3 (da) *	2001-07-31	2012-04-23	Genzyme Global S A R L	Fremgangsmåder til at mobilisere progenitor/stamceller
PL369856A1 (en)	2001-12-21	2005-05-02	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005007838A1 (ja) *	2003-06-27	2005-01-27	Asahi Kasei Kabushiki Kaisha	細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株
WO2005002522A2 (en) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions and methods for treating tissue ischemia
WO2005017160A2 (en) *	2003-08-13	2005-02-24	Children's Hospital Medical Center	Mobilization of hematopoietic cells
WO2005017161A2 (en)	2003-08-13	2005-02-24	Children's Hospital Medical Center	Chimeric peptides for the regulation of gtpases
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
JP2008509928A (ja) *	2004-08-13	2008-04-03	アノーメドインコーポレイテッド	前駆／幹細胞を動員するためのケモカインの組み合わせ
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
CA2586765A1 (en) *	2004-11-05	2006-12-28	The General Hospital Corporation	Purposeful movement of human migratory cells away from an agent source
KR101604799B1 (ko)	2005-06-13	2016-03-28	클리브랜드 바이오랩스, 아이엔씨.	리포펩티드를 사용하여 아폽토시스에 대항하는 보호방법
US20070043012A1 (en) *	2005-08-19	2007-02-22	Bridger Gary J	Methods to enhance chemotherapy
EP1924606A4 (en) *	2005-08-25	2010-01-13	Repair Technologies Inc	DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
CA2643209A1 (en) *	2006-02-24	2007-09-20	Genzyme Corporation	Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (en) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Method for induction of differentiation of stem and progenitor cells
CN101500595A (zh) *	2006-08-07	2009-08-05	健赞股份有限公司	组合治疗
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (en) *	2008-08-29	2010-03-04	Genzyme Corporation	Cxcr4 antagonists for kidney injury
EP2493295A4 (en)	2009-10-28	2013-05-08	Ford Henry Health System	METHOD FOR MINIMIZING LESIONS DUE TO RADIATION EXPOSURE
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR20140045411A (ko)	2011-05-16	2014-04-16	젠자임 코포레이션	Ｃｘｃｒ４ 길항제의 용도
US20160030522A1 (en) *	2013-03-15	2016-02-04	Leonard B. Miller	Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
US11890348B2 (en)	2015-09-18	2024-02-06	The General Hospital Corporation	Localized delivery of anti-fugetactic agent for treatment of cancer
CA3008279A1 (en)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methods for treating cancer
CN109069426B (zh)	2015-12-14	2021-10-29	X4 制药有限公司	治疗癌症的方法
WO2017106630A1 (en)	2015-12-18	2017-06-22	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
WO2017112894A1 (en)	2015-12-22	2017-06-29	X4 Pharmaceuticals, Inc.	Methods for treating immunodeficiency disease
CA3019394A1 (en)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methods for treating cancer
EP3471716A1 (en) *	2016-06-16	2019-04-24	Centre National De La Recherche Scientifique	Cxcr4 receptor-binding compounds useful for increasing interferon level
ES2870920T3 (es)	2016-06-21	2021-10-28	X4 Pharmaceuticals Inc	Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh)	2016-06-21	2019-04-16	X4 制药有限公司	Cxcr4抑制剂及其用途
EP3472129A4 (en)	2016-06-21	2019-12-04	X4 Pharmaceuticals, Inc.	CXCR4 INHIBITORS AND USES THEREOF
WO2018049118A1 (en)	2016-09-09	2018-03-15	The General Hospital Corporation	Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
US11453706B2 (en)	2016-09-09	2022-09-27	The General Hospital Corporation	HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018049120A1 (en)	2016-09-09	2018-03-15	The General Hospital Corporation	Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
WO2018106738A1 (en)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Brush-arm star polymers, conjugates and particles, and uses thereof
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
CN111712262A (zh) *	2017-12-06	2020-09-25	美真达治疗公司	用于动员造血干细胞和祖细胞的给药方案
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP3727371A4 (en) *	2017-12-19	2021-10-27	GPCR Therapeutics, Inc.	GPCR HETEROMER INHIBITORS AND THEIR USES
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en)	2019-10-08	2024-08-13	The Regents Of The University Of California	Methods and compositions for hematopoietic stem cell mobilization
CA3171250A1 (en)	2020-03-10	2021-09-16	E. Lynne KELLEY	Methods for treating neutropenia
EP4146797A1 (en)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Treatment for neurodegenerative diseases
WO2023056444A1 (en)	2021-10-01	2023-04-06	Janssen Pharmaceutica N.V.	Methods of increasing progenitor cell production
WO2025224720A1 (en)	2024-04-24	2025-10-30	Biolinerx Ltd.	Methods of selecting treatment regimen against solid tumors
CN118987175A (zh) *	2024-08-13	2024-11-22	广东壹加再生医学研究院有限公司	普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) *	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
CA2069886A1 (en)	1989-10-23	1991-04-24	David Love	Multi-site metal chelating agents
US5021409A (en) *	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
FR2672051B1 (fr) *	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en)	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
DE69309487T2 (de)	1992-11-13	1997-10-23	Univ Washington	Peripheralisierung hämatopoietischer stammzellen
GB9400411D0 (en)	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) *	1995-02-02	1995-03-22	Abuljadayel Ilham M S	A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) *	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
GB9511357D0 (en)	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US6506770B1 (en) *	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
WO2000018885A1 (en) *	1998-09-29	2000-04-06	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2305787A1 (en)	2000-05-09	2001-11-09	The University Of British Columbia	Cxcr4 antagonist treatment of hematopoietic cells
ES2156581T5 (es) *	1998-03-30	2015-01-21	Northwest Biotherapeutics, Inc.	Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
WO1999065507A1 (en) *	1998-06-19	1999-12-23	The General Hospital Corporation	Modulating platelet function
CA2244554A1 (en) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition of graft versus host disease
JP2002529502A (ja) *	1998-11-17	2002-09-10	スミスクライン・ビーチャム・コーポレイション	血小板減少症の治療法
EP1016413A1 (en) *	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
AP1654A (en)	1999-03-24	2006-09-01	Anormed Inc	Chemokine receptor binding heterocyclic compounds.
WO2000066112A1 (en) *	1999-05-03	2000-11-09	Smithkline Beecham Corporation	Cxcr-4 receptor antagonists - thrombopoietin mimetics
AU2334301A (en) *	1999-12-17	2001-06-25	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
EP1286684B1 (en)	2000-05-09	2004-04-28	The University Of British Columbia	use of cxcr4 antagonists for treating autoimmune diseases and cancer
MXPA02012067A (es) *	2000-06-05	2004-08-19	Univ Columbia	Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
US6734191B2 (en)	2000-09-15	2004-05-11	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
DE60137435D1 (de)	2000-09-15	2009-03-05	Anormed Inc	Chemokin rezeptor bindenden heterozyklische verbindungen
HK1052011A1 (zh)	2000-09-15	2003-08-29	Anormed Inc.	趋化因子受体结合杂环化合物
DE60136476D1 (de)	2000-09-29	2008-12-18	Anormed Inc	-stickstoffhaltigen zyklischen polyaminen und deren verbindungen
CA2431611A1 (en)	2001-01-23	2002-08-01	P&G-Clairol, Inc.	Primary intermediates for oxidative coloration of hair
US7169750B2 (en)	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
DK1411918T3 (da)	2001-07-31	2012-04-23	Genzyme Global S A R L	Fremgangsmåder til at mobilisere progenitor/stamceller
PL369856A1 (en)	2001-12-21	2005-05-02	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Ceased
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 EP EP02750370A patent/EP1411918B1/en not_active Revoked
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/en not_active Ceased
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko not_active Expired - Lifetime
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/en not_active Revoked
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 CA CA2455559A patent/CA2455559C/en not_active Expired - Lifetime
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/en not_active Withdrawn
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 BR BR0211570-0 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en not_active Expired - Lifetime
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I1/el unknown
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I2/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
FR12C0042I1 (fr)	2012-08-10
PL364673A1 (en)	2004-12-13
US20060223180A1 (en)	2006-10-05
CN102302493B (zh)	2015-08-12
NL301031I1 (nl)	2020-02-05
SI2371361T1 (sl)	2019-10-30
KR20040020075A (ko)	2004-03-06
CY1122199T1 (el)	2020-05-29
LU92033I2 (fr)	2012-08-27
LU92033I9 (da)	2019-01-03
BE2019C544I2 (da)	2021-07-19
JP5137288B2 (ja)	2013-02-06
KR100996378B1 (ko)	2010-11-25
HK1063005A1 (en)	2004-12-10
HUP0402360A2 (hu)	2005-02-28
ES2380009T3 (es)	2012-05-07
WO2003011277A3 (en)	2003-05-22
EP3632425A1 (en)	2020-04-08
NZ530169A (en)	2007-04-27
EP1411918A2 (en)	2004-04-28
US20080063624A1 (en)	2008-03-13
CN102302493A (zh)	2012-01-04
NO20150674A1 (no)	2015-05-27
US20190216773A1 (en)	2019-07-18
US20110129448A1 (en)	2011-06-02
JP2004538303A (ja)	2004-12-24
BRPI0211570B1 (pt)	2020-01-28
FR19C1058I1 (da)	2019-11-22
NO20040407L (no)	2004-03-19
IL159312A0 (en)	2004-06-01
NL300537I2 (da)	2017-02-02
US7935692B2 (en)	2011-05-03
BR0211570A (pt)	2004-07-13
CY2019038I1 (el)	2020-05-29
CY2019038I2 (el)	2020-05-29
ES2742730T3 (es)	2020-02-17
LTPA2019018I1 (lt)	2019-12-10
EP1411918A4 (en)	2007-11-14
PT2371361T (pt)	2019-09-10
LUC00139I2 (da)	2021-02-10
JP2008195730A (ja)	2008-08-28
ZA200400658B (en)	2005-07-27
MXPA04000982A (es)	2004-04-20
CY2012017I2 (el)	2015-08-05
CA2455559C (en)	2012-01-10
BRPI0211570B8 (pt)	2021-05-25
ATE538785T1 (de)	2012-01-15
CY1112633T1 (el)	2015-08-05
NO344632B1 (no)	2020-02-17
EP2371361B1 (en)	2019-08-07
NO2020003I1 (no)	2020-03-05
EP2371361A1 (en)	2011-10-05
LUC00139I1 (da)	2019-11-27
IL159312A (en)	2015-05-31
US6987102B2 (en)	2006-01-17
US20170049747A1 (en)	2017-02-23
US20030130250A1 (en)	2003-07-10
NO336989B1 (no)	2015-12-14
AU2002318927B2 (en)	2007-01-04
LTC2371361I2 (lt)	2021-09-27
CN1561208A (zh)	2005-01-05
FR19C1058I2 (fr)	2020-10-23
RU2309741C2 (ru)	2007-11-10
US20130273009A1 (en)	2013-10-17
PT1411918E (pt)	2012-03-06
KR20090130152A (ko)	2009-12-17
SI1411918T1 (sl)	2012-04-30
NL301031I2 (nl)	2020-07-20
LT2371361T (lt)	2019-09-10
US20060193826A1 (en)	2006-08-31
EP1411918B1 (en)	2011-12-28
US7897590B2 (en)	2011-03-01
CA2455559A1 (en)	2003-02-13
WO2003011277A2 (en)	2003-02-13
RU2004105961A (ru)	2005-03-20
CN1561208B (zh)	2010-11-10
CY2012017I1 (el)	2015-08-05
US20150246019A1 (en)	2015-09-03
DK1411918T3 (da)	2012-04-23
NO2016011I1 (no)	2016-06-10

Publication	Publication Date	Title
LTC2371361I2 (lt)	2021-09-27	Pirmtakų/kamieninių ląstelių suaktyvinimo būdai
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu)	2001-04-28	VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR930006027A (ko)	1993-04-20	엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
EP2308877A4 (en)	2012-03-14	Imidazopyridine-2-ON DERIVATIVE
AR035218A1 (es)	2004-05-05	Inhibidores vla-4
ES2164164T3 (es)	2002-02-16	Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
TW200633979A (en)	2006-10-01	Method
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
DE69524103D1 (de)	2002-01-03	Fluorinierte 2-nitroimidazole analoge zur detektion von hypoxischen tumorzellen
ATE258050T1 (de)	2004-02-15	Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
IL136911A0 (en)	2001-06-14	Heterocyclic topoisomerase poisons
ATE46511T1 (de)	1989-10-15	Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
WO1999023092A3 (en)	1999-08-05	3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
EA200000527A2 (ru)	2000-12-25	Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
WO2007106063A3 (en)	2007-12-21	Methods for increasing blood flow and/or promoting tissue regeneration
FR2823749B1 (fr)	2004-02-20	Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
TH58467A3 (th)	2003-09-22	ไบไซโคล (2.2.1) เฮพเทนส์ และสารประกอบที่เกี่ยวข้อง